Abstract: A method for stabilizing blood glucose levels and reducing the hyperglycemia associated with Type II diabetes. Synthetic chromic tripicolinate is administered either orally or parenterally to a human in need thereof at a dosage of between about 1,000 amd 10,000 micrograms per day.

Abstract: Compounds of formula (1) are described: wherein L1 is a covalent bond or a linker atom or group; R is a carboxylic acid (—CO2H) or a derivative threof; R6 and R7 which may be the same or different is each an atom or group —L2(Alk2)tL3R12 in which L2, L3, Alk2 and t are as previously defined and R12 is a hydrogen or halogen atom or an —OR9, —NR9R10, —NO2, —CN, —CO2R9, —CONR9R10, —COR9, —N(R9)COR10, —N(R9)CSR10, —SO2N(R9)(R10), —N(R9)SO2R9, —N(R9)CON(R10)(R11), —N(R9)CSN(R10)(R11), —N(R9)SO2N(R10)(R11), or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group provided that R6 and R7 are not both hydrogen atoms and when R7 is a hydrogen atom then R4 and R5 is each a hydrogen or halogen atom or an alkyl, alkoxy or nitro group; and the salts, solvates, hydrates and N-oxides thereof, for use in modulating cell adhesion.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for protecting tissue from the harmful effects of apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.

Abstract: The invention provides the use of dipyridoxyl or aminopolycarboxylic acid based chelating agents, metal chelates and salts thereof, in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of atherosclerosis and related conditions in the human or non-human animal body.

Abstract: Disclosed herein are anti-inflammatory and anti-ulcer copper coordination compounds and a process for using them in the treatment of arthritis and gastrointestinal ulcers in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with: 1. aromatic carboxylic acids or their alkaline earth salts; 2. heterocyclic carboxylic acids or their alkaline earth salts; 3. amino acids or their alkaline earth salts; 4. amines; and 5. suitably substituted steroids. The process disclosed comprises administering to experimental animals, orally or parentrally (subcutaneously), in controlled dosages, the aforementioned copper coordination compounds for the treatment of inflammation (i.e., arthritis) and ulcers of the gastrointestinal tract.

Abstract: This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a monoamine oxidase B inhibitor, characterised in that the composition is formulated to promote pre-gastric absorption of said monoamine oxidase B inhibitor. A process for preparing such a composition and the use of such a composition for the treatment of Parkinson's disease, the treatment and/or prophylaxis of depression and the treatment and/or prophylaxis of Alzheimer's disease are also provided.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: A natural method for promoting fat, and weight loss while decreasing food cravings comprising administrating to an individual in need thereof L-carnitine, chromium, coenzyme Q10, creatine, lipoic acid, niacin, pyruvate, riboflavin, and thiamine. Pyruvate is a major promoter of the oxidation of dietary fuels like carbohydrates and fatty acids in the citric acid cycle. L-carnitine allow the transport of fatty acids into the mitochondria were they can be degraded in the citric acid cycle. Lipoic acid is a major intracellular antioxidant, and component of key enzymes in the citric acid cycle. Niacin, riboflavin, and thiamine are key components of enzymes that lead to the breakdown of dietary fuel molecules such as fatty acids, amino acids, and carbohydrates that enter the citric acid cycle. The breakdown of these dietary fuels leads to the production of high energy hydrogen atoms. Coenzyme Q10 accepts these hydrogen atoms and utilizes them for cellular energy production.

Abstract: Organic complexes of vanadium are provided, having the general structure VL3, where V is vanadium(III) and L is a monoprotic bidentate ligand that forms a five-membered, unsaturated vanadium containing ring, having vanadium coordinating oxygen or sulfur ring heteroatoms, and where the vanadium containing ring is fused to a six-membered heterocyclic ring. Preferably L is a hydroxypyrone or a hydroxypyridinone. The complexes have a number of uses, including the treatment of elevated blood glucose and related disorders, treatment of proliferative disorders, etc.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in combination with at least one of a cyclooxygenase inhibitor, an acid, a mucolytic and a salicin-containing herb. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: The present invention relates to non-spherical and/or non-platelet pyrithione particles. Also disclosed is a method for producing non-spherical and/or non-platelet particles of pyrithione salts, comprising reacting pyrithione acid or a water-soluble salt of pyrithione and a water-soluble polyvalent metal salt in the presence of an ionic surfactant composition at temperature from about 20° C. to about 60° C. and at a pH from 4-9 to produce non-spherical and/or non-platelet particles of pyrithione salts. The present invention further relates to particles made by the above methods and products, such as shampoos, soaps, and skin-care medicaments made using these particles.

Abstract: Organovanadium complexes, and more specifically hydroxyoxovanadium(V), &mgr;-oxo dimeric oxovanadium(V) and cis-dioxovanadium(V) complexes, are provided. The complexes may be formulated into a pharmaceutical composition. The complexes and/or compositions may be used in the treatment of a variety of disease states, including use as anti-proliferative and/or anti-metastatic agents and/or to treat drug resistant tumors and/or to methods of reducing the ability of tumors to metastasize and/or for the treatment of diabetes, arthritis, multiple sclerosis, diseases involving passageways of the body, and autoimmune diseases including but not limited to psoriasis and lupus.

Abstract: A probe for a surface-enhanced Raman scattering spectrometer is provided for injection into a cell in order to detect trace amounts of a compound within that cell. The probe has a spherical shape with a diameter less than one micrometer and preferably in the 10-500 nanometer range. The nanoprobes can have a receptor coating related to the specific compound to be detected by the probe. A process for producing, injecting and utilizing the nanoprobes are described.

Abstract: A method of treatment or inhibition of tumors including the steps of: (i) exchanging one or more of the eight phenyl substituents in the compound [M(dppe)2]+ where M is selected from Au(I), Ag(I) and Cu(I) by 2, 3, or 4 pyridyl substituents to provide a compound having anti-tumor activity and an octanol/water partition coefficient between 0.01 and 25.5; and (ii) administering said compound to a subject requiring treatment which compound has selective toxicity to cancer cells including cisplatin resistant human carcinoma cell lines.

Abstract: There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl,R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl,R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, andR.sub.6, independently of R.sub.1, is lower alkoxycarbonyl,or salts thereof, provided that at least one salt-forming group is present.The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS.

Abstract: A food supplement compositions combining suitable precursor substrates with folic acid, whereby methionine is produced in sufficient quantity to produce a sufficient quantity of met-enkephalin specially formulated for coping with stressful assaults upon the human body. By a coenzymatic mechanism folic acid effectively accelerates the transformation of a substrate primarily comprising DL-phenylalanine, L-phenylalanine, L-glutamine, and L-tryptophan to met-enkephalin end product. Use of this food supplement enables enkephalins to accumulate within the human hypothalamus, thereby increasing the levels of endogenous opioids. By increasing endogenous opioid levels, the human body is engendered with a self-regulating faculty for coping with stressful assaults upon physiological and psychological equilibrium.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in combination with at least one of a cyclooxygenase inhibitor, an acid, a mucolytic and a salicin-containing herb. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: Enhancement of attentional processing is attained by administration of an endorphinase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including Rhodiola rosea extract (Pharmaline) and/or Huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non-addictive. Use of the dopamine precursors L-phenylalanine, or L-Tyrosine, the enkephalinase inhibitor D-phenylalanine, and/or the serotonin precursor -hydroxytryptophan and a natural acetylcholenesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency.

Abstract: Dermatological/cosmetic compositions for reducing or decelerating human hair loss comprise an effective hair loss-reducing amount of combinatory immixture of (a) at least one antifungal agent and (b) at least one halogenated antibacterial agent other than a macrolide or pyranoside, characteristically formulated in a topically physiologically acceptable medium therefor.

Abstract: Stable antiseptic compositions having broad spectrum, fast acting, and profound persistent effect without significant irritation of the tissue to which they are applied are disclosed. The broad spectrum, fast acting component of the present invention comprises one or more antimicrobial alcohols, antimicrobial lipids, or mixtures thereof. The persistent component of the present invention comprises one or more antimicrobial lipids, pyridine-containing compounds, nitrogen-containing antibitics, preservatives, or mixtures thereof, which preferably bind to either or both of the skin surface and intracellular structures within the epidermis. Additional components include antioxidants, emulsifying agents, acidifiers, thickeners, and coloring and texturing compounds. Preferred antiseptic formulations comprise an antimicrobial alcohol such as 70% n-propanol, an antimicrobial lipid such as free fatty acids and/or fatty acid esters, and zinc omadine.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: A method of increasing the amount of anagen hair in a human comprising applying an azole or zinc pyrithione, or mixtures thereof to an area of a human where an increase in the amount of anagen hair is desired. Also provided is a method of reducing the shedding of hair in a human comprised of applying an effective amount of an azole or zinc pyrithione to an area of a human where such a reduction is desired. Further provided is a method of increasing the diameter of a hair shaft comprising topically applying an effective amount of an azole to an area of a human where an increase in the diameter is desired.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: (4-oxy-3-(aryl)phenyl)pyridine compounds, in free or acid addition salt form, are useful as pharmaceuticals for treatment and prophylaxis of inflammation, particularly inflammatory or obstructive diseases of the airways, e.g. for asthma therapy. Preferred compounds are novel biphenyl pyridines, biphenyl benzamides and biphenyl phenylcarboxy compounds. The compounds are selective inhibitors of PDE 4 isoenzyme activity and also act to down regulate or inhibit TNF-.alpha. release.

Abstract: Seborrheic dermatitis of the scalp is treated by a synergistic combination of a cytotoxic agent and an antifungal agent.

Abstract: Disclosed herein is hair-care cosmetic compositions comprising iodopropynyl butylcarbamate and/or a solution of zinc pyrithione in N-acyl ethylenediamine triacetate.

Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light. Suitable compound include compounds of the formula:Rh(R.sub.1)(R.sub.2)(R.sub.3).sup.3+where R.sub.1 and R.sub.2 are each independently aryl, heteroaryl, substituted aryl or substituted heteroaryl of 1 to 5 rings, and R.sub.3 is a group of the formula ##STR1## where x and z are each independently an integer from 1 to 4 and y is an integer from 1 to 2, and R.sub.4, R.sub.5, and R.sub.6 are each independently H--, halo, HO--, H.sub.2 N--, CN--, O.sub.2 N--, HS--, O.sub.3 S--, O.sub.3 SO--, --COOH, --CONH.sub.2, R, RO--, RNH--, R.sub.a R.sub.b N--, RO.sub.3 S--, RO.sub.3 SO--, --COOR, --CONHR, or --CONR.sub.a R.sub.b, where R, R.sub.a and R.sub.

Abstract: The present invention relates to non-spherical and/or non-platelet pyrithione particles. Also disclosed is a method for producing non-spherical and/or non-platelet particles of pyrithione salts, comprising reacting pyrithione or a water-soluble salt of pyrithione and a water-soluble polyvalent metal salt in the presence of a dispersant at a temperature from about 20.degree. C. to about 60.degree. C. to produce non-spherical and/or non-platelet particles of pyrithione salts. The present invention further relates to particles made by the above methods and products, such as shampoos, soaps, and skin-care medicaments made using these particles.

Abstract: A mildew resistant organopolysiloxane composition is provided, including (A) an organopolysiloxane having silanol groups or alkoxyl groups, (B) a hydrolyzable silane, and (C) a triazolyl group-containing compound. The composition further includes (D) bis(2-pyridylthio-1-oxide) zinc salt. The composition is excellent in mildew resistance and its durability as well as excellent in heat resistance and weathering properties. The cured products hardly undergo discoloration if exposed to UV light or heat. The composition is useful as a sealant to be used at wet locations.

Abstract: The current invention discloses useful amidino derivative useful as nitric oxide synthase inhibitors.

Abstract: Compositions comprising an ionene polymer and a pyrithione salt are disclosed which are synergistically effective compared to the respective components alone in controlling the growth of microorganisms in or on a material or medium. Methods to control the growth of microorganisms and prevent spoilage caused by microorganisms with the use of the compositions of the present invention are also disclosed.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in combination with at least one of a cyclooxygenase inhibitor, an acid, a mucolytic and a salicin-containing herb. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: One or more formulations for treating psoriasis and other skin disorders characterized by redness, itching, flaking, scaling, and plaque-type growth. The formulation includes a carrier component, one or more active ingredient components, and a surfactant component. The carrier preferably includes an alcohol in substantially equal volume with isopropyl myristate. The active ingredient component preferably includes a superpotent or high-potency corticosteroid such as clobetasol propionate, an anti-flaking ingredient such as zinc pyrithione, or a combination of the two. It may also include an anti-fungal compound. The surfactant component preferably includes an alkyl sulfate such as sodium lauryl sulfate. The formulations made by applied topically either in spray form or as a direct-contact liquid.

Abstract: This invention relates to a pharmaceutical composition for the treatment of acne having an acne reduction component in an amount sufficient to reduce the redness and blemishes associated with acne. The invention also relates to pharmaceutical compositions having, in addition to the acne reduction component, a skin cell conditioning component in an amount sufficient to properly regulate the keratin and sebum production of the skin cells, thereby inhibiting the appearance of acne. In a preferred form, the skin cell conditioning component is a chromium component. In another preferred form, the composition further includes at least one of a vitamin C source, burdock root, yellow dock root, horsetail extract, a catechin-based composition, a vitamin B.sub.1 source, a vitamin B.sub.2 source, a vitamin B.sub.3 source, a vitamin B.sub.5 source, and a vitamin E source. In a more preferred form, the invention also includes at least one amino acid component, a magnesium component, a selenium component, and biotin.

Abstract: An enteral nutritional product for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions may further comprise at least one of a cyclooxygenase inhibitor, an acid and a mucolytic. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: The present invention also relates to a method of using these novel materials, and other materials, to treat or prevent a disease caused by serotonin or a method of treating or preventing platelet aggregation. The compounds used are piperidine derivatives having the formula (I): ##STR1## wherein the various substituents are defined below.

Abstract: The invention relates to a method of treating sleep disorders in a patient in need thereof comprising the administration of a hypnotically effective amount of a non-allosteric GABA.sub.A agonist.

Abstract: A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 .mu.g of chromium and between 25 .mu.g and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.

Abstract: A food supplement compositions combining suitable precursor substrates with folic acid, whereby methionine is produced in sufficient quantity to produce a sufficient quantity of met-enkephalin specially formulated for coping with stressful assaults upon the human body. By a coenzymlatic mechanism folic acid effectively accelerates the transformation of a substrate primarily comprising DL-phenylalanine, L-phenylalanine, L-glutamine, and L-tryptophan to met-enkephalin end product. Use of this food supplement enables enkephalins to accumulate within the human hypothalamus, thereby increasing the levels of endogenous opioids. By increasing endogenous opioid levels, the human body engendered with a self-regulating faculty for coping with stressful assaults upon physiological and psychological equilibrium.

Abstract: A locally administrable topical pharmaceutical composition is provided for prevention or treatment of skin conditions associated with hyperproliferation of skin cells and/or an immunologically mediated disorder, e.g., psoriasis, atopical dermatitis, contact dermatitis, seborrhoeic dermatitis, lupus and the like. The composition contains a topical carrier and spirogermanium or a structurally related azaspirane. Also provided are methods for using the novel composition and laminated patches which may be applied to the skin to administer the composition thereto.

Abstract: A method for promoting weight and fat loss comprising administering to an individual in need thereof hydroxycitrate, carnitine and an agent which promotes the rapid intramitochondrial generation of oxaloacetate or induces endogenous production of pyruvate. This method also promotes an increase in lean body mass.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions may further comprise at least one of a cyclooxygenase inhibitor, an acid and a mucolytic. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: Disclosed herein is hair-care cosmetic compositions comprising iodopropynyl butylcarbamate and/or a solution of zinc pyrithione in N-acyl ethylenediamine triacetate.

Abstract: Disclosed is a process for inhibiting the formation of discoloration in an aqueous composition selected from the group consisting of water-based paint, adhesive, caulk and sealant compositions, and combinations thereof, wherein said discoloration is caused by the presence of ferric ion or cupric ion together with pyrithione in said composition. The process comprises contacting the composition with a discoloration-inhibiting amount of a zinc compound selected from the group consisting of zinc salts of organic acids, zinc salts of inorganic acids, zinc hydroxide, zinc oxide, and combinations thereof. Also disclosed is an aqueous antimicrobial composition protected against discoloration attributable to the presence of ferric ion or cupric ion therein.

Abstract: Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anemia.